March, 2026, In Singapore, Eutropics today announced a research collaboration with the National University of Singapore (NUS) to evaluate the company’s PRIMAB™ functional biomarker platform in Multiple Myeloma. The partnership will explore how PRIMAB’s predictive insights into tumor cell apoptosis can inform individualized therapeutic strategies for patients with this complex hematologic cancer. The study will be led by Dr. Stephen Chong, a leading investigator in cancer cell physiology and mechanisms of drug response at NUS. Dr. Chong’s expertise complements Eutropics’ mission to translate systems-level understanding of cell death regulation into clinical tools that guide precision oncology.“This collaboration represents an important step in extending the PRIMAB platform to Multiple Myeloma,” said Michael Cardone. “We look forward to working with Dr. Chong’s team to better define how functional biomarkers can improve treatment decision-making”
